AstraZeneca Pharma India launches Selumetinib capsule in India

10 Aug 2023 Evaluate

AstraZeneca Pharma India has launched Selumetinib 10 mg and 25 mg capsule (Koselugo) in India. Selumetinib (Koselugo) is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).

Earlier, the company had received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib (Koselugo). 

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.


Astrazeneca Pharma I Share Price

8376.65 -119.05 (-1.40%)
19-Mar-2026 09:45 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1766.00
Dr. Reddys Lab 1272.70
Cipla 1255.05
Zydus Lifesciences 883.75
Lupin 2276.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×